Equity Overview
Price & Market Data
Price: $0.53
Daily Change: -$0.0305 / 5.75%
Range: $0.514 - $0.578
Market Cap: $30,889,638
Volume: 307,009
Performance Metrics
1 Week: -6.20%
1 Month: -5.66%
3 Months: -65.21%
6 Months: -72.35%
1 Year: -86.90%
YTD: -61.66%
Company Details
Employees: 105
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-116 which is in discovery stage for the treatment of obesity; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.